Cargando…
Digital Therapeutics for MCI and Alzheimer’s disease: A Regulatory Perspective — Highlights From The Clinical Trials on Alzheimer’s Disease conference (CTAD)
Autores principales: | Shuren, J., Doraiswamy, P. M. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer International Publishing
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8920745/ https://www.ncbi.nlm.nih.gov/pubmed/35542995 http://dx.doi.org/10.14283/jpad.2022.28 |
Ejemplares similares
-
Synaptic dysfunction and oxidative stress in Alzheimer’s disease: Emerging mechanisms
por: Forero, D A, et al.
Publicado: (2006) -
Alzheimer disease in post-menopausal women: Intervene in the critical window period
por: Jamshed, Nayer, et al.
Publicado: (2014) -
Tackling a Major Deficiency of Diversity in Alzheimer’s Disease Therapeutic Trials: An CTAD Task Force Report
por: Raman, Rema, et al.
Publicado: (2022) -
State Approaches to Therapeutic Interchange in Community Pharmacy Settings: Legislative and Regulatory Authority
por: Vanderholm, Thomas, et al.
Publicado: (2018) -
Parkinson's Disease and Wearable Technology: An Indian Perspective
por: Bagrodia, Vaishali, et al.
Publicado: (2022)